Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 28 September 1984:
Vol. 225. no. 4669, pp. 1480 - 1482
DOI: 10.1126/science.6332378
Prev | Table of Contents | Next

Articles

Science, Vol 225, Issue 4669, 1480-1482
Copyright © 1984 by American Association for the Advancement of Science

articles

Pargyline prevents MPTP-induced parkinsonism in primates

JW Langston, I Irwin, EB Langston, and LS Forno

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin which produces permanent parkinsonism in human and nonhuman primates. Treatment of squirrel monkeys with pargyline, a monoamine oxidase (MAO) inhibitor, prevents both clinical and neuropathological evidence of the neurotoxic effects of MPTP. Pargyline also inhibits conversion of MPTP to 1-methyl-4-phenylpyridinium ion (MPP+), a metabolic step that occurs rapidly after administration of MPTP in animals not treated with pargyline. It is proposed that the conversion of MPTP to MPP+, possibly involving MAO, may be important for the neurotoxic effects of MPTP to take place, and MPTP itself may not be the neurotoxic agent.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Chemical Genomic Profiling for Identifying Intracellular Targets of Toxicants Producing Parkinson's Disease.
J. Doostzadeh, R. W. Davis, G. N. Giaever, C. Nislow, and J. W. Langston (2007)
Toxicol. Sci. 95, 182-187
   Abstract »    Full Text »    PDF »
A novel formulation of selegiline for the treatment of Parkinson's disease.
J. W. Tetrud and W. C. Koller (2004)
Neurology 63, S2-S6
   Full Text »
Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease.
P. Jenner (2004)
Neurology 63, S13-S22
   Full Text »
PET Imaging of Monoamine Oxidase B in Peripheral Organs in Humans.
J. S. Fowler, J. Logan, G.-J. Wang, N. D. Volkow, W. Zhu, D. Franceschi, N. Pappas, R. Ferrieri, C. Shea, V. Garza, et al. (2002)
J. Nucl. Med. 43, 1331-1338
   Abstract »    Full Text »    PDF »
Echogenicity of the Substantia Nigra: Association With Increased Iron Content and Marker for Susceptibility to Nigrostriatal Injury.
D. Berg, W. Roggendorf, U. Schroder, R. Klein, T. Tatschner, P. Benz, O. Tucha, M. Preier, K. W. Lange, K. Reiners, et al. (2002)
Arch Neurol 59, 999-1005
   Abstract »    Full Text »    PDF »
The Selective Toxicity of 1-Methyl-4-phenylpyridinium to Dopaminergic Neurons: The Role of Mitochondrial Complex I and Reactive Oxygen Species Revisited.
K. Nakamura, V. P. Bindokas, J. D. Marks, D. A. Wright, D. M. Frim, R. J. Miller, and U. J. Kang (2000)
Mol. Pharmacol. 58, 271-278
   Abstract »    Full Text »
MPTP-Induced Modulation of Neurotransmitters in SH-SY5Y Human Neuroblastoma Cells.
X. Song and M. Ehrich (1998)
International Journal of Toxicology 17, 677-701
   Abstract »    PDF »
Molecular Analysis of Neurotransmitter Transport into Secretory Vesicles.
Y. Liu, C. Waites, D. Krantz, P. Tan, and R.H. Edwards (1996)
Cold Spring Harb Symp Quant Biol 61, 747-758
   Abstract »    PDF »
l-Methyl-4-phenylpyridinium (MPP+) but not 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Serves as Methyl Donor for Dopamine: A Possible Mechanism of Action.
C. G. Charlton (1992)
J Geriatr Psychiatry Neurol 5, 114-118
   Abstract »    PDF »
Early Combination of Selegiline and Low-Dose Levodopa as Initial Symptomatic Therapy in Parkinson's Disease: Experience in 26 Patients Receiving Combined Therapy for 26 Months.
T. S. Elizan, D. A. Moros, and M. D. Yahr (1991)
Arch Neurol 48, 31-34
   Abstract »    PDF »
DATATOP: A Multicenter Controlled Clinical Trial in Early Parkinson's Disease: Parkinson Study Group.
(1989)
Arch Neurol 46, 1052-1060
   Abstract »    PDF »
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.
J. Tetrud and J. Langston (1989)
Science 245, 519-522
   Abstract »    PDF »
Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET.
J. Fowler, R. MacGregor, A. Wolf, C. Arnett, S. Dewey, D Schlyer, D Christman, J Logan, M Smith, H Sachs, et al. (1987)
Science 235, 481-485
   Abstract »    PDF »
Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin.
R. D'Amato, Z. Lipman, and S. Snyder (1986)
Science 231, 987-989
   Abstract »    PDF »
Distinct monoamine oxidase A and B populations in primate brain.
K. Westlund, R. Denney, L. Kochersperger, R. Rose, and C. Abell (1985)
Science 230, 181-183
   Abstract »    PDF »
Brain enzyme is the target of drug toxin.
R Lewin (1984)
Science 225, 1460-1462
   PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)